Author/Authors :
Li Tsai، Jun نويسنده Department of Family Medicine, Cheng Ching General Hospital, Taichung, Taiwan , , Ju Wu، Ming نويسنده Division of Nephrology, Department of Medicine, Taichung Veterans General Hospital, Taichung, Taiwan , , Hsu Chen، Cheng نويسنده Division of Nephrology, Department of Medicine, Taichung Veterans General Hospital, Taichung, Taiwan , , Feng Tsai، Shang نويسنده Division of Nephrology, Department of Medicine, Taichung Veterans General Hospital, Taichung, Taiwan ,
Abstract :
Encapsulating peritoneal sclerosis (EPS) is a rare but devastating complication of peritoneal dialysis (PD). Tamoxifen has been generally well-tolerated, even without randomized controlled trials. Herein, we report a case of a patient undergoing 12 years of PD who developed EPS and calciphylaxis simultaneously. We also provide a comprehensive discussion about the association between EPS and calciphylaxis. Moreover, although tamoxifen is used in EPS due to its inhibition of fibroblast-transforming growth factor beta (TGFβ) production, it may worsen the calciphylaxis due to a hypercoagulable state. We suggest avoiding the use of tamoxifen for EPS in patients with superimposed calciphylaxis.
